Claims

 An expression vector comprising a nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which is selected from: a carbohydrate binding domain of a collectin; a carbohydrate binding domain of a galectin; a carbohydrate binding domain of a C-type lectin; or an amino acid sequence which can bind to a carbohydrate on a glycoprotein, said carbohydrate being chosen from the group: D-mannose, D-glucose, D-fucose, L-fucose, N-acetyl-beta-D-glucosamine, N-acetyl-beta-D-glucosamine, a sialic acid;

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide, said ligand being chosen from the group: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a counterreceptor for a T cell costimulatory molecule.

- 2. The expression vector of claim 1, wherein said first amino acid sequence is N-terminal to said second amino acid sequence.
- 3. The expression vector of claim 1, wherein said first amino acid sequence is C-terminal to said second amino acid sequence.
- 4. The expression vector of claim 1, wherein said first amino acid sequence can bind to a sialic acid on a glycoprotein, said sialic acid comprising at least one of the following carbohydrate structures: N-acetylneuraminic acid, alpha-NeuNAc-[2->6]-Gal, alpha-NeuNAc-[2->6]-GalNAc, alpha-NeuNAc-[2->3]-Gal.

5. The expression vector of claim 1, wherein said first amino acid sequence comprises a carbohydrate-binding domain of a naturally occurring lectin.

- 6. The expression vector of claim 1, wherein said first amino acid sequence comprises at least about 10 contiguous amino acids of a hemagglutinin.
- 7. The expression vector of claim 6, wherein said hemagglutinin is an influenza virus hemagglutinin.
- 8. The expression vector of claim 7, wherein said contiguous amino acids of an influenza hemagglutinin are contiguous amino acids of an influenza hemagglutinin HA1 domain.
- 9. The expression vector of claim 7, wherein said influenza virus is an influenza A virus.
- 10. The expression vector of claim 9, wherein said influenza virus is of a subtype that infects humans.
- 11. The expression vector of claim 9, wherein said influenza virus is of an H1 subtype.
- 12. The expression vector of claim 11, wherein said influenza virus is from the strain A/PR/8/34.
- 13. The expression vector of claim 10, wherein said influenza virus is of an H2 or H3 subtype.

14. The expression vector of claim 7, wherein said influenza virus is of a subtype that does not infect humans.

- 15. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a mammalian cell surface polypeptide.
- 16. The expression vector of claim 15, wherein said ligand for a cell surface polypeptide is a ligand for a mouse cell surface polypeptide.
- 17. The expression vector of claim 15, wherein said ligand for a cell surface polypeptide is a ligand for a human cell surface polypeptide.
- 18. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a leukocyte.
- 19. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of an antigen presenting cell.
- 20. The expression vector of claim 19, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a professional antigen presenting cell.
- 21. The expression vector of claim 18, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a dendritic cell.
- 22. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a mouse GM-CSF receptor.

23. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse GM-CSF.

- 24. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises a mouse GM-CSF.
- 25. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a human GM-CSF receptor.
- 26. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human GM-CSF.
- 27. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises a human GM-CSF.
- 28. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interleukin.
- 29. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interleukin.
- 30. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interleukin.
- 31. The expression vector of claim 28, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.

32. The expression vector of claim 28, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interleukin.

- 33. The expression vector of claim 32, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
- 34. The expression vector of claim 28, wherein said ligand for a cell surface polypeptide comprises an interleukin.
- 35. The expression vector of claim 34, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
- 36. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a chemokine.
- 37. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse chemokine.
- 38. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human chemokine.
- 39. The expression vector of claim 36, wherein said chemokine is a C-C cytokine.
- 40. The expression vector of claim 36, wherein said chemokine is a C-X-C cytokine.

41. The expression vector of claim 36, wherein said cell surface polypeptide is chosen from the group: CXCR-1, CXCR-2, CXCR-3, CXCR-4, CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8.

- 42. The expression vector of claim 36, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
- 43. The expression vector of claim 36, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of a chemokine.
- 44. The expression vector of claim 43, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
- 45. The expression vector of claim 36, wherein said ligand for a cell surface polypeptide comprises a chemokine.
- 46. The expression vector of claim 45, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2,

MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.

- 47. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interferon.
- 48. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interferon.
- 49. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interferon.
- 50. The expression vector of claim 47, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
- 51. The expression vector of claim 47, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interferon.
- 52. The expression vector of claim 51, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
- 53. The expression vector of claim 47, wherein said ligand for a cell surface polypeptide comprises an interferon.
- 54. The expression vector of claim 53, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.

55. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a mouse TNF-alpha receptor.

- 56. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse TNF-alpha.
- 57. The expression vector of any claim 1, wherein said ligand for a cell surface polypeptide comprises a mouse TNF-alpha.
- 58. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a human TNF-alpha receptor.
- 59. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human TNF-alpha.
- 60. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises a human TNF-alpha.
- 61. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a mouse flt-3 receptor.
- 62. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse flt-3.
- 63. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises a mouse flt-3.

64. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide is a ligand for a human flt-3 receptor.

- 65. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human flt-3.
- 66. The expression vector of claim 1, wherein said ligand for a cell surface polypeptide comprises a human flt-3.
- 67. The expression vector of claim 1, wherein said encoded fusion polypeptide further comprises a linker interposed between said first and second amino acid sequences.
- 68. The expression vector of claim 67, wherein said linker has the formula $(Gly_xSer)_n$, wherein n is an integer between 1 and 15, and x is an integer between 1 and 10.
- 69. The expression vector of claim 1, wherein said encoded fusion polypeptide further comprises a secretory signal sequence.
- 70. The expression vector of claim 1, which is a eukaryotic expression vector.
- 71. The expression vector of claim 70, which is a yeast expression vector.
- 72. The expression vector of claim 70, which is a mammalian expression vector.
- 73. The expression vector of claim 1, which comprises an inducible promoter.
- 74. A host cell comprising a nucleic acid molecule encoding a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which is selected from: a carbohydrate binding domain of a collectin; a carbohydrate binding domain of a galectin; a carbohydrate binding domain of a C-type lectin; or an amino acid sequence which can bind to a carbohydrate on a glycoprotein, said carbohydrate being chosen from the group: D-mannose, D-glucose, D-fucose, L-fucose, N-acetyl-beta-D-glucosamine, N-acetyl-beta-D-glucosamine, a sialic acid;

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide, said ligand being chosen from the group: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule.

- 75. The host cell of claim 74, wherein said first amino acid sequence is N-terminal to said second amino acid sequence.
- 76. The host cell of claim 74, wherein said first amino acid sequence is C-terminal to said second amino acid sequence.
- 77. The host cell of claim 74, wherein said first amino acid sequence can bind to a sialic acid on a glycoprotein, said sialic acid comprising at least one of the following carbohydrate structures: N-acetylneuraminic acid, alpha-NeuNAc-[2->6]-Gal, alpha-NeuNAc-[2->6]-GalNAc, alpha-NeuNAc-[2->3]-Gal.
- 78. The host cell of claim 74, wherein said first amino acid sequence comprises a carbohydrate-binding domain of a naturally occurring lectin.
- 79. The host cell of claim 74, wherein said first amino acid sequence comprises at least about 10 contiguous amino acids of a hemagglutinin.

80. The host cell of claim 79, wherein said hemagglutinin is an influenza virus hemagglutinin.

- 81. The host cell of claim 80, wherein said contiguous amino acids of an influenza hemagglutinin are contiguous amino acids of an influenza hemagglutinin HA1 domain.
- 82. The host cell of claim 80, wherein said influenza virus is an influenza A virus.
- 83. The host cell of claim 80, wherein said influenza virus is of a subtype that infects humans.
- 84. The host cell of claim 82, wherein said influenza virus is of an H1 subtype.
- 85. The host cell of claim 83, wherein said influenza virus is from the strain A/PR/8/34.
- 86. The host cell of claim 82, wherein said influenza virus is of an H2 or H3 subtype.
- 87. The host cell of claim 80, wherein said influenza virus is of a subtype that does not infect humans.
- 88. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a mammalian cell surface polypeptide.
- 89. The host cell of claim 88, wherein said ligand for a cell surface polypeptide is a ligand for a mouse cell surface polypeptide.

90. The host cell of claim 88, wherein said ligand for a cell surface polypeptide is a ligand for a human cell surface polypeptide.

- 91. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a leukocyte.
- 92. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of an antigen presenting cell.
- 93. The host cell of claim 19, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a professional antigen presenting cell.
- 94. The host cell of claim 91, wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a dendritic cell.
- 95. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a mouse GM-CSF receptor.
- 96. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse GM-CSF.
- 97. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises a mouse GM-CSF.
- 98. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a human GM-CSF receptor.
- 99. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human GM-CSF.

100. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises a human GM-CSF.

- 101. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interleukin.
- 102. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interleukin.
- 103. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interleukin.
- 104. The host cell of claim 101, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
- 105. The host cell of claim 101, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interleukin.
- 106. The host cell of claim 105, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
- 107. The host cell of claim 101, wherein said ligand for a cell surface polypeptide comprises an interleukin.

108. The host cell of claim 107, wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.

- 109. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a chemokine.
- 110. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse chemokine.
- 111. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human chemokine.
- 112. The host cell of claim 109, wherein said chemokine is a C-C cytokine.
- 113. The host cell of claim 109, wherein said chemokine is a C-X-C cytokine.
- 114. The host cell of claim 109, wherein said cell surface polypeptide is chosen from the group: CXCR-1, CXCR-2, CXCR-3, CXCR-4, CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8.
- 115. The host cell of claim 109, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.

116. The host cell of claim 109, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of a chemokine.

- 117. The host cell of claim 116, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
- 118. The host cell of claim 109, wherein said ligand for a cell surface polypeptide comprises a chemokine.
- 119. The host cell of claim 118, wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, I-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
- 120. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interferon.
- 121. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interferon.

122. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interferon.

- 123. The host cell of claim 120, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
- 124. The host cell of claim 120, wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interferon.
- 125. The host cell of claim 124, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
- 126. The host cell of claim 120, wherein said ligand for a cell surface polypeptide comprises an interferon.
- 127. The host cell of claim 126, wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
- 128. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a mouse TNF-alpha receptor.
- 129. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse TNF-alpha.
- 130. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises a mouse TNF-alpha.
- 131. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a human TNF-alpha receptor.

132. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human TNF-alpha.

- 133. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises a human TNF-alpha.
- 134. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a mouse flt-3 receptor.
- 135. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse flt-3.
- 136. The host cell of any claim 74, wherein said ligand for a cell surface polypeptide comprises a mouse flt-3.
- 137. The host cell of claim 74, wherein said ligand for a cell surface polypeptide is a ligand for a human flt-3 receptor.
- 138. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human flt-3.
- 139. The host cell of claim 74, wherein said ligand for a cell surface polypeptide comprises a human flt-3.
- 140. The host cell of claim 74, wherein said encoded fusion polypeptide further comprises a linker interposed between said first and second amino acid sequences.

141. The host cell of claim 140, wherein said linker has the formula $(Gly_xSer)_n$, wherein n is an integer between 1 and 15, and x is an integer between 1 and 10.

- 142. The host cell of claim 74, wherein said encoded fusion polypeptide further comprises a secretory signal sequence.
- 143. The host cell of claim 74, which is a prokaryotic cell.
- 144. The host cell of claim 74, which is a eukaryotic cell.
- 145. The host cell of claim 144, which is a yeast cell.
- 146. The host cell of claim 144, which is a mammalian cell.
- 147. The host cell of claim 144, which is an insect cell.